Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Neoplasms 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Mitotane 4Cisplatin 3pembrolizumab 2cixutumumab 2Etoposide 2Doxorubicin 2Dichlorodiphenyldichloroethane 2sodium thiosulfate 1relacorilant 1pegfilgrastim 1milademetan 1gossypol acetic acid 1cabozantinib 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Sunitinib 1Streptozocin 1Platinum 1Nivolumab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Ethane 1Cytoreduction Surgical Procedures 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adrenocortical Carcinoma × gossypol acetic acid × Clear all
NCT00848016 2014-05-07

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡